Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma.

Ikeda T, Ishihara H, Takagi T, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Kondo T, Tanabe K.

Clin Genitourin Cancer. 2019 Dec 17. pii: S1558-7673(19)30385-4. doi: 10.1016/j.clgc.2019.12.012. [Epub ahead of print]

PMID:
31917171
2.

Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.

Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K.

Int J Clin Oncol. 2019 Dec 19. doi: 10.1007/s10147-019-01605-9. [Epub ahead of print]

PMID:
31858306
3.

Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma.

Ishiyama R, Ishihara H, Kondo T, Takagi T, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K.

In Vivo. 2019 Nov-Dec;33(6):2153-2160. doi: 10.21873/invivo.11717.

4.

Phase I study of cellular therapy using ex vivo expanded NK cell from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.

Tanaka J, Tanaka N, Wang YH, Mitsuhashi K, Ryuzaki M, Iizuka Y, Watanabe A, Ishiyama M, Shinohara A, Kazama H, Hagiwara S, Yoshinaga K, Kougen Y, Kobayashi H, Kanno H, Shiseki M.

Haematologica. 2019 Aug 8. pii: haematol.2019.226696. doi: 10.3324/haematol.2019.226696. [Epub ahead of print]

5.

Is it safe to continue antithrombotic agents before prostate biopsy?

Tanabe K, Hattori T, Kobayashi H, Koike K, Maki Y, Arai T, Otsuka T, Suzuki Y, Kondo Y, Kawamura N.

Prostate Int. 2019 Jun;7(2):78-81. doi: 10.1016/j.prnil.2018.06.004. Epub 2018 Jul 5.

6.

Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma.

Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K.

Target Oncol. 2019 Aug;14(4):453-463. doi: 10.1007/s11523-019-00660-6.

PMID:
31359231
7.

Association between tumor contact surface area and parenchymal volume change in robot-assisted laparoscopic partial nephrectomy carried out using the enucleation technique.

Takagi T, Yoshida K, Kondo T, Kobayashi H, Iizuka J, Okumi M, Ishida H, Tanabe K.

Int J Urol. 2019 Jul;26(7):745-751. doi: 10.1111/iju.14004. Epub 2019 Apr 18.

PMID:
31001853
8.

Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.

Ishihara H, Takagi T, Kondo T, Homma C, Tachibana H, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K.

Urol Oncol. 2019 Jun;37(6):355.e21-355.e29. doi: 10.1016/j.urolonc.2019.03.003. Epub 2019 Mar 29.

PMID:
30935847
9.

Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.

Takagi T, Fukuda H, Kondo T, Ishihara H, Yoshida K, Kobayashi H, Iizuka J, Okumi M, Ishida H, Tanabe K.

Target Oncol. 2019 Apr;14(2):179-186. doi: 10.1007/s11523-019-00634-8.

PMID:
30927174
10.

Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.

Yoshida K, Takagi T, Kondo T, Kobayashi H, Iizuka J, Fukuda H, Ishihara H, Okumi M, Ishida H, Tanabe K.

Jpn J Clin Oncol. 2019 Jun 1;49(6):576-580. doi: 10.1093/jjco/hyz040.

PMID:
30924496
11.

Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.

Ishihara H, Takagi T, Kondo T, Tachibana H, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K.

Med Oncol. 2019 Mar 16;36(4):35. doi: 10.1007/s12032-019-1261-5.

PMID:
30879157
12.

Peritumoral pseudocapsule status according to pathological characteristics from robot-assisted laparoscopic partial nephrectomy for localized renal cell carcinoma.

Takagi T, Yoshida K, Kondo T, Kobayashi H, Iizuka J, Okumi M, Ishida H, Nagashima Y, Tanabe K.

Int J Urol. 2019 Apr;26(4):446-450. doi: 10.1111/iju.13901. Epub 2019 Jan 16.

PMID:
30650470
13.

Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study.

Ishihara H, Kondo T, Takagi T, Tachibana H, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Tanabe K.

Target Oncol. 2018 Oct;13(5):611-619. doi: 10.1007/s11523-018-0591-0.

PMID:
30232691
14.

Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study.

Kondo T, Sasa N, Yamada H, Takagi T, Iizuka J, Kobayashi H, Yoshida K, Fukuda H, Ishihara H, Tanabe K, Tsuzuki T.

Pathol Int. 2018 Oct;68(10):543-549. doi: 10.1111/pin.12718. Epub 2018 Sep 6.

PMID:
30187581
15.

Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy.

Ishiyama R, Kondo T, Takagi T, Iizuka J, Kobayashi H, Omae K, Fukuda H, Ishihara H, Tanabe K.

J Endourol. 2018 Oct;32(10):928-933. doi: 10.1089/end.2017.0779. Epub 2018 Sep 25.

PMID:
30141346
16.

Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma.

Takagi T, Yoshida K, Kobayashi H, Kondo T, Iizuka J, Okumi M, Ishida H, Fukuda H, Ishihara H, Tanabe K.

Jpn J Clin Oncol. 2018 Sep 1;48(9):860-863. doi: 10.1093/jjco/hyy106.

PMID:
30113653
17.

Possible Application of Ascites-infiltrating Gamma-delta T Cells for Adoptive Immunotherapy.

Abe Y, Kobayashi H, Akizawa Y, Ishitani K, Hashimoto K, Matsui H.

Anticancer Res. 2018 Jul;38(7):4327-4331. doi: 10.21873/anticanres.12732.

PMID:
29970569
18.

Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma.

Ishihara H, Takagi T, Kondo T, Iwamoto K, Tachibana H, Yoshida K, Omae K, Iizuka J, Kobayashi H, Tanabe K.

Jpn J Clin Oncol. 2018 Jul 1;48(7):667-672. doi: 10.1093/jjco/hyy078.

PMID:
29860353
19.

Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.

Ishihara H, Takagi T, Kondo T, Tachibana H, Yoshida K, Omae K, Iizuka J, Kobayashi H, Tanabe K.

Int J Clin Oncol. 2018 Jun;23(3):559-567. doi: 10.1007/s10147-018-1241-3. Epub 2018 Jan 11.

PMID:
29327159
20.

Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug.

Tanaka Y, Murata-Hirai K, Iwasaki M, Matsumoto K, Hayashi K, Kumagai A, Nada MH, Wang H, Kobayashi H, Kamitakahara H, Okamura H, Sugie T, Minato N, Toi M, Morita CT.

Cancer Sci. 2018 Mar;109(3):587-599. doi: 10.1111/cas.13491. Epub 2018 Feb 4.

Supplemental Content

Loading ...
Support Center